Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

HEMACARE CORP /CA/ Form 8-K September 15, 2003

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549

> > FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2003

HEMACARE CORPORATION (Exact Name of Registrant as Specified in its Charter)

CALIFORNIA (State or other jurisdiction of incorporation)

000-15223 95-3280412 (Commission File No.) (IRS Employer Identification No.)

> 21101 Oxnard Street Woodland Hills, CA 91367 (Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (818) 226-1968

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number Description

99.1 Press Release issued by HemaCare, dated September 15, 2003

Item 9. REGULATION FD DISCLOSURE

On September 15, 2003, HemaCare Corporation issued a press release announcing the closure of some of its blood management programs in order to achieve sustained profitability. A copy is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the exhibits, will not be treated as "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

SIGNATURES

Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 15, 2003

HEMACARE CORPORATION

/s/ Judi Irving

Judi Irving, Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by HemaCare, dated
	September 15, 2003